Abstract
Osteoarthritis - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist’s new report,
“Osteoarthritis - Pipeline Assessment and Market Forecasts to
2017” is an essential source of information and analysis on the global
osteoarthritis therapeutics market. The report identifies the key trends
shaping and driving the global osteoarthritis therapeutics market. The report
also provides insight on the competitive landscape and the emerging players
expected to bring significant shift in the market positioning of the existing
market leaders. Most importantly, the report provides valuable insight on the
pipeline products within the global osteoarthritis therapeutics market.
Scope
- Annualized global osteoarthritis therapeutics market revenues data from 2001
to 2009, forecast forward for 7 years to 2017.
- Geographies covered in
this report include the US, the UK, Italy, Spain, Germany, France, and
Japan.
- Pipeline analysis data providing a split across different phases,
mechanism of action being developed and emerging trends. The first-in-class
drugs act through new mechanisms of action such as Nuclear Factor-KappaB
(NF-kB) activation inhibitors, TNF alpha blockers, cannabinoid receptor (CB2)
agonists and protease inibitors.
- Analysis of the current and future
market competition in the global osteoarthritis therapeutics. Key future
market players covered are Pfizer, Novartis AG, J&J and Crystalgenomics.
-
Insightful review of the key industry drivers, restraints and challenges. Each
trend is independently researched to provide qualitative analysis of its
implications.
- Key topics covered include strategic competitor
assessment, market characterization, unmet needs and implications for future
market associated with osteoarthritis therapeutics market.
Reasons to buy
The report will enhance your decision making capability in a more rapid and
time sensitive manner. It will allow you to:
- Develop and design your
in-licensing and out-licensing strategies through review of pipeline products
and technologies and by identifying companies with the most robust
pipeline.
- Develop business strategies by understanding the trends
shaping and driving the global osteoarthritis therapeutics market.
-
Drive revenues by understanding key trends, innovative products and
technologies, market segments and companies likely to impact the global
osteoarthritis therapeutics market in future.
- Formulate effective sales
and marketing strategies by understanding the competitive landscape and by
analyzing the performance of various competitors.
- Identify emerging
players with potentially strong product portfolio and create effective
counter-strategies to gain competitive advantage.
- Organize your sales
and marketing efforts by identifying the market categories and segments that
present maximum opportunities for consolidations, investments and strategic
partnerships.
- What’s the next big thing in the global
osteoarthritis therapeutics market landscape? - Identify, understand and
capitalize.
Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2
Osteoarthritis: Introduction 5
2.1 Overview 5
2.2 GlobalData Pipeline
Report Guidance 6
3 Osteoarthritis Therapeutics Market: Market
Characterization 7
3.1 Osteoarthritis Market Forecast and CAGR 8
3.2
Drivers and Barriers for the Osteoarthritis Therapeutics Market 10
3.2.1
Drivers for the Osteoarthritis Therapeutics Market 10
3.2.2 Barriers for
the Osteoarthritis Therapeutics Market 10
3.3 Opportunity and Unmet Need
11
3.4 Key Takeaway 12
4 Osteoarthritis Therapeutics Market:
Competitive Assessment 13
4.1 Overview 13
4.2 Strategic Competitor
Assessment 13
4.3 Product Profiles of the Major Marketed Products in the
Osteoarthritis Therapeutics Market 14
4.3.1 Celebrex (Celecoxib) 14
4.3.2 Mobic (meloxicam) 15
4.3.3 Voltaren Gel (diclofenac sodium) 15
4.3.4 Hyalgan (sodium hyaluronate) 16
4.3.5 Ultram ER (tramadol extended
release) 16
4.4 Key Takeaway 17
5 Osteoarthritis Therapeutics Market:
Pipeline Assessment 18
5.1 Overview 18
5.2 Strategic Pipeline
Assessment 18
5.2.1 Technology Trends Analytic Framework 18
5.3
Osteoarthritis Therapeutics - Promising Drugs under Clinical Development
19
5.4 Molecule Profile for Promising Drugs under Clinical Development
20
5.4.1 SD6010 20
5.4.2 CG100649 21
5.5 OA Market -
Clinical Pipeline by Mechanism of Action 22
5.6 Osteoarthritis Pipeline
- Pipeline by Clinical Phases of Development 23
5.6.1 Osteoarthritis
Therapeutics - Phase III Clinical Pipeline 24
5.6.2 Osteoarthritis
Therapeutics - Phase II Clinical Pipeline 25
5.6.3 Osteoarthritis
Therapeutics - Phase I Clinical Pipeline 26
5.6.4 OA Therapeutics
- Pre-clinical Pipeline 27
5.6.5 Osteoarthritis Therapeutics -
Discovery Pipeline 27
5.6.6 Osteoarthritis Therapeutics -
Discontinued Pipeline 28
5.7 Key Takeaway 28
6 Osteoarthritis Market:
Implications for Future Market Competition 29
7 Osteoarthritis Market:
Future Players in the Osteoarthritis Market 30
7.1 Introduction 30
7.2
Novartis Pharma AG (Novartis) 31
7.2.1 Overview 31
7.2.2
Osteoarthritis Disease Portfolio 31
7.2.3 SMC021 31
7.3 Pfizer Inc.
32
7.3.1 Overview 32
7.3.2 Osteoarthritis Disease Portfolio 33
7.3.3 SD6010 33
7.4 Johnson and Johnson 33
7.4.1 Company Overview
33
7.4.2 Osteoarthritis Disease Portfolio 34
7.5 CrystalGenomics, Inc.
34
7.5.1 Company Overview 34
7.5.2 Osteoarthritis Disease Portfolio
34
7.5.3 CG100649 35
8 Osteoarthritis Therapeutics Market: Appendix
36
8.1 Definitions 36
8.2 Acronyms 36
8.3 Research Methodology
37
8.3.1 Coverage 37
8.3.2 Secondary Research 38
8.3.3 Forecasting
38
8.3.4 Primary Research 41
8.3.5 Expert Panel Validation 41
8.4
Contact Us 41
8.5 Disclaimer 41
8.6 Sources 42
1.1 List of
Tables
Table 1: Osteoarthritis Therapeutics Market, Global, Revenues
($bn), 2001-2009 8
Table 2: Osteoarthritis Therapeutics Market, Global,
Revenues ($bn), 2009-2017 9
Table 3: Osteoarthritis Therapeutics Market,
Major Marketed Products Comparison, 2010 17
Table 4: Osteoarthritis
Therapeutics - Most Promising Drugs Under Clinical Development, 2010
19
Table 5: Osteoarthritis Therapeutics Market, Phase III Clinical
Pipeline, 2010 24
Table 6: Osteoarthritis Therapeutics - Phase II
Clinical Pipeline, 2010 25
Table 7: Osteoarthritis Therapeutics, Phase I
Clinical Pipeline, 2010 26
Table 8: Osteoarthritis Therapeutics Market,
Discovery Pipeline, 2010 27
Table 9: Osteoarthritis Therapeutics -
Discontinued Pipeline, 2010 28
Table 10: Novartis Pharmaceutical -
Osteoarthritis Pipeline Products, 2010 31
Table 11: Pfizer Inc.
Corporation, Osteoarthritis Pipeline Products, 2010 33
Table 12: Johnson
and Johnson - Osteoarthritis Pipeline Products, 2010 34
Table 13:
Abbott Laboratories, Osteoarthritis Pipeline Products, 2010 34
1.2
List of Figures
Figure 1: Osteoarthritis Therapeutics Market, Global,
Revenues ($bn), 2001-2009 8
Figure 2: Osteoarthritis Therapeutics Market,
Global, Revenue ($bn) Forecasts, 2009-2017 9
Figure 3: Opportunity and
Unmet Need in the Osteoarthritis Therapeutics Market 11
Figure 4:
Osteoarthritis Therapeutics Market, Strategic Competitor Assessment of the
Major Marketed Products, 2010 14
Figure 5: Osteoarthritis Therapeutics
Market, Technology Trends Analytic Framework of the Pipeline, 2010 18
Figure 6: Osteoarthritis Therapeutics Market, Technology Trends Analytic
Framework of the Pipeline, Description, 2010 19
Figure 7:
Osteoarthritis Therapeutics Market, Clinical Pipeline by Mechanism of Action
(%), 2010 22
Figure 8: Osteoarthritis Therapeutics Market, Pipeline by
Phase of Clinical Development (%), 2010 23
Figure 9: Implications for
Future Market Competition in the Osteoarthritis Market, 2010 29
Figure 10:
Osteoarthritis Therapeutics Market, Clinical Pipeline by Company, 2010 30
Figure 11: GlobalData Market Forecasting Model 40
